Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
(2023)
Dataset
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Dataset]. https://doi.org/10.1158/1078-0432.c.6532623.v1
Purpose:
EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer.
Patients and Methods:
This randomized phase II, two-part, multicenter trial included n...
Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.